Product news from the 02/20/07 News Brief

Share this article:
Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for propranolol hydrochloride extended-release (ER) capsules in 60mg, 80mg, 120mg and 160mg strengths. Propranolol hydrochloride ER capsules are the generic version of Wyeth’s beta blocker, Inderal LA, which had US sales of approximately $201 million for the same strengths for the 12-month period ended Dec. 31, 2006, according to IMS Health. The FDA has granted priority review status to Gilead Science’s hypertension drug ambrisentan on a priority basis. Ambrisentan is a potential treatment for pulmonary arterial hypertension, a type of high blood pressure that affects the lungs and leads to heart failure. Priority FDA review typically takes six months, only half as long as the one year a drug is typically under review.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.